OncoMatch/Clinical Trials/NCT05989347
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Is NCT05989347 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Dapagliflozin 10mg for breast cancer.
Treatment: Dapagliflozin 10mg — The primary objective of the study is to assess metabolic plasma markers of insulin resistance in patients with early-stage HER2-negative breast cancers receiving dapagliflozin concomitant with neoadjuvant therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) negative
HER2-negative - either ER+ or triple negative - invasive breast cancer as defined by ASCO CAP guidelines
Allowed: ESR1 positive
either ER+ or triple negative
Disease stage
Required: Stage I, II, III
Prior therapy
Lab requirements
Blood counts
peripheral granulocyte count of > 1,500/mm3; platelet count > 100,000/mm3; hemoglobin >9 g/dL
Kidney function
serum creatinine < 1.5 x ULN; eGFR < 25 excluded
Liver function
total bilirubin < 1.5 x ULN; AST and ALT each < 1.5 x ULN
adequate organ function to tolerate chemotherapy, as defined by: peripheral granulocyte count of > 1,500/mm3; platelet count > 100,000/mm3; hemoglobin >9 g/dL; total bilirubin < 1.5 x ULN; AST and ALT each < 1.5 x ULN; serum creatinine < 1.5 x ULN; INR/PT/PTT each < 1.5 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Yale Cancer Center Smilow Cancer Hospital · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify